Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cervical cancer staging

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Cervical cancer staging. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2006-002251-33 Sponsor Protocol Number: 01 Start Date*: 2006-10-10
    Sponsor Name:University of Vienna
    Full Title: Hypoxia Imaging with the novel Radiopharmaceutical 18F Fluoroazomycin Arabinoside (FAZA)- Prognostic impact in Cervical Cancer .
    Medical condition: Twenty-five patients with cervical carcinoma (T2Nx or TxN1) will be included in the present study. In addition to the routine pre-therapeutical staging of cervical cancer, 18FAZA PET will be perfor...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003507-19 Sponsor Protocol Number: HOPE9 Start Date*: 2020-09-10
    Sponsor Name:AZIENDA USL TOSCANA NORD OVEST
    Full Title: “Phase III, randomized, double-blind, placebo-controlled multicenter study to evaluate the efficacy of pre-surgical HPV 9-valent vaccination in women treated with electrosurgical excision with diat...
    Medical condition: Prevention of recurrence after a first episode of high-grade cervical intraepithelial neoplasia (CIN2 +) up to initially invasive cervical cancer (FIGO IA1)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    21.1 100000004872 10056576 Cervical intraepithelial neoplasia LLT
    21.1 10022891 - Investigations 10064328 Human papilloma virus test positive PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003622-33 Sponsor Protocol Number: 2017/2608 Start Date*: 2018-04-03
    Sponsor Name:Gustave Roussy
    Full Title: Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer
    Medical condition: Locally Advanced Cervical Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008229 Cervical cancer LLT
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-011682-91 Sponsor Protocol Number: 64Cu-ATSM-UTERO-01/2009 Start Date*: 2009-09-29
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: Role of 64Cu-ATSM PET/CT for the localization of hypoxic areas in uterine cervical cancer
    Medical condition: Patients affected by uterine cervical cancer (sensitivity for localizing area of hypoxia within tumoral masses will be evaluated )
    Disease: Version SOC Term Classification Code Term Level
    9.1 10007493 LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004638-99 Sponsor Protocol Number: 2105xx1 Start Date*: 2017-11-13
    Sponsor Name:Rigshospitalet, Department of Clinical Physiology, Nuclear Medicine and PET
    Full Title: Phase II trial: uPAR PET/CT and FDG PET/CT for preoperative staging of gynecological cancers
    Medical condition: gynecological cancers: Vulvar cancer endometrial cancer (uterine cancer) cervical cancer ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021045 10007107 Cancer of ovary LLT
    20.0 100000020935 10007050 Cancer LLT
    20.0 100000021101 10047743 Vulval cancer NOS LLT
    20.0 100000021008 10007063 Cancer of endometrium LLT
    20.0 100000020977 10008229 Cervical cancer LLT
    Population Age: Elderly Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003759-19 Sponsor Protocol Number: CervixErbitux-1 Start Date*: 2006-11-29
    Sponsor Name:Department of Gynecological Oncology, University Hospital, Örebro
    Full Title: Cetuximab and cisplatin in addition to radiotherapy in the treatment of stage IIA-III carcinoma of the uterine cervix - a pilot phase II study.
    Medical condition: Stage IIA-III carcinoma of the uterine cervix.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10041848 Squamous cell carcinoma of the cervix LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002707-18 Sponsor Protocol Number: EFFECT Start Date*: 2012-11-14
    Sponsor Name:FONDAZIONE SANDRO PITIGLIANI PER LA LOTTA CONTRO I TUMORI-ONLUS
    Full Title: EFFECT: A randomized phase II study to evaluate the EFficacy and impact on Function of two different doses of nab-paclitaxEl in elderly patients with advanCed breasT cancer
    Medical condition: Patients aged 65 years or older with histologically or cytologically confirmed breast cancer, locally recurrent and/or metastatic; any estrogen/progesterone receptor status; HER2 receptor negative ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003965-27 Sponsor Protocol Number: OCTO-072 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Oxford
    Full Title: A phase I dose escalation safety study combining the ATR inhibitor M6620 with chemoradiotherapy in oesophageal cancer & other sold cancers using time to event continual reassessment method
    Medical condition: Stage A1 and B: Oesophageal carcinoma Stage A2: Any advanced solid tumours (carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003068-28 Sponsor Protocol Number: 77946 Start Date*: 2021-09-29
    Sponsor Name:University Medical Center Utrecht
    Full Title: Sentinel lymph node detection of cervical occult lymph node metastases in patients with parotid gland carcinoma by means of sentinel node biopsy using 68-galium-tilmanocept PET-CT.
    Medical condition: The IMP will be used for the identification of sentinel lymph node(s) in patients with parotid gland carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026329 Malignant neoplasm of parotid gland LLT
    20.0 100000004848 10072873 Sentinel lymph node mapping LLT
    20.1 100000004848 10073554 Sentinel node biopsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000513-37 Sponsor Protocol Number: Z1031 Start Date*: 2006-09-13
    Sponsor Name:ACOSOG
    Full Title: A Randomised Phase III Trial comparing 16 to 18 weeks of neoadjuvant Exemestane (25mg daily), Letrozole (2.5mg), or Anastrozole(1mg) in postmenopausal Women with Clinical Stage II and III Estrogen...
    Medical condition: Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003429-28 Sponsor Protocol Number: 109823 Start Date*: 2014-04-28
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IV, observer-blind, randomized, controlled, multicentric study to assess the safety and immunogenicity of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix™) administered intramuscul...
    Medical condition: For active immunization of women from the age of 10 years onwards to prevent cervical cancer (squamous-cell carcinoma and adenocarcinoma) by protecting against incident and persistent infections, c...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10071147 Human papilloma virus immunization LLT
    19.0 100000004848 10058580 Human papilloma virus serology test LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002324-27 Sponsor Protocol Number: MYL-1401H-3001 Start Date*: 2015-04-22
    Sponsor Name:Mylan GmbH
    Full Title: Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL 1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Che...
    Medical condition: chemotherapy-induced neutropenia in patients with stage II/III breast cancer receiving docetaxel, doxorubicin, and cyclophosphamide (TAC) anti-cancer chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-003596-12 Sponsor Protocol Number: C/21/07 Start Date*: 2008-01-28
    Sponsor Name:Imperial College of Science Technology and Medicine
    Full Title: A neoadjuvant study of chemotherapy versus endocrine therapy in postmenopausal patients with primary breast cancer
    Medical condition: This trial will involve postmenopausal patients with histologically confirmed breast tumours in whom it is felt cytoreductive systemic therapy would enable conservative surgery to be carried out.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2015-002773-38 Sponsor Protocol Number: AIO-KRK-0214 Start Date*: 2016-12-20
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: mFOLFOX6 vs. mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial
    Medical condition: Patients with locally advanced rectal or rectosigmoid cancer staged cT3 CRM-negative with MRI
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010036 Colorectal carcinoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-005186-10 Sponsor Protocol Number: EGF105485 Start Date*: 2006-09-12
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2 Overexpressing Breast Cancer
    Medical condition: Women with early-stage ErbB2-overexpressing breast cancer. Eligible women must have had an initial diagnosis of histologically or cytologically confirmed invasive breast cancer (Stage I through St...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) LT (Completed) ES (Completed) BE (Completed) DK (Completed) LV (Completed) GR (Completed) SK (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000432-10 Sponsor Protocol Number: 26866138MMY2084 Start Date*: 2013-05-23
    Sponsor Name:DUTCH BELGIAN COOPERATIVE GROUP FOR HEMATOLOGY ONCOLOGY - HOVON
    Full Title: A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF PROLONGED THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PAT...
    Medical condition: Patients with Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000578-20 Sponsor Protocol Number: CLDK378A2205 Start Date*: 2015-03-16
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-Positive Non-Small Cell Lung Cancer (NSCLC) metastatic to ...
    Medical condition: Non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024233 Leptomeningeal metastases LLT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006128 Brain metastases LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) GB (Completed) DE (Completed) NL (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004024-37 Sponsor Protocol Number: A6181109 Start Date*: 2007-07-05
    Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017
    Full Title: SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF ADJUVANT SUNITINIB VS. PLACEBO IN SUBJECTS WITH HIGH RISK RCC
    Medical condition: Adjuvant treatment of subjects with “high risk” Renal Cell Carcinoma (RCC) following nephrectomy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (Completed) CZ (Completed) DE (Completed) GR (Completed) AT (Completed) IT (Completed) IE (Completed) SE (Completed) PL (Completed) SK (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000279-34 Sponsor Protocol Number: UOB2886 Start Date*: 2018-04-20
    Sponsor Name:Research, Enterprise & Development (RED), University of Bristol
    Full Title: Mistletoe And Breast Cancer (MAB): A pilot study for a randomized double-blind controlled trial
    Medical condition: Breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-000427-17 Sponsor Protocol Number: CY503C1 Start Date*: 2007-10-26
    Sponsor Name:CYTAVIS BioPharma GmbH
    Full Title: A phase II multicenter study to test progression- free and overall survival of CY-503 in the treatment of patients with unresectable stage IV metastatic melanoma after antineoplastic treatment failure
    Medical condition: unresectable progressive metastatic melanoma stage IV after antineoplastic treatmet failure
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027152 Melanoma of skin (malignant) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 13:00:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA